J
James Rucker
Researcher at King's College London
Publications - 78
Citations - 2747
James Rucker is an academic researcher from King's College London. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 17, co-authored 45 publications receiving 1562 citations. Previous affiliations of James Rucker include University of Alberta & South London and Maudsley NHS Foundation Trust.
Papers
More filters
Journal ArticleDOI
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Robin L. Carhart-Harris,Mark Bolstridge,James Rucker,Camilla M. Day,David Erritzoe,Mendel Kaelen,Michael A P Bloomfield,James Rickard,Ben Forbes,Amanda Feilding,David Taylor,Steve Pilling,Valerie Curran,David J. Nutt +13 more
TL;DR: Preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression is provided and motivates further trials, with more rigorous designs, to better examine the therapeutic potential of this approach.
Journal ArticleDOI
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
Robin L. Carhart-Harris,Mark Bolstridge,Mark Bolstridge,Camilla M. Day,Camilla M. Day,James Rucker,James Rucker,Rosalind Watts,David Erritzoe,Mendel Kaelen,Bruna Giribaldi,Michael A P Bloomfield,Stephen Pilling,James Rickard,Ben Forbes,Amanda Feilding,David Taylor,HV Curran,David J. Nutt +18 more
TL;DR: Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort.
Journal ArticleDOI
Psychiatry & the psychedelic drugs. Past, present & future.
TL;DR: Clinical trials using psychedelics pre and post prohibition are summarised, the methodological challenges of performing good quality trials in this area are discussed, and a strategic approach to the legal and regulatory barriers to licensing psychedelics as a treatment in mainstream psychiatry is considered.
Journal ArticleDOI
Psychedelics in the treatment of unipolar mood disorders: a systematic review.
James Rucker,Luke A Jelen,Luke A Jelen,Sarah Flynn,Kyle D. Frowde,Allan H. Young,Allan H. Young +6 more
TL;DR: The evidence overall strongly suggests that psychedelics should be re-examined in modern clinical trials for their use in unipolar mood disorders and other non-psychotic mental health conditions.
Journal ArticleDOI
Male-Biased Autosomal Effect of 16p13.11 Copy Number Variation in Neurodevelopmental Disorders
Maria Tropeano,Joo Wook Ahn,Richard Dobson,Gerome Breen,James Rucker,Abhishek Dixit,Deb K. Pal,Peter McGuffin,Anne Farmer,Peter White,Joris Andrieux,Evangelos Vassos,Caroline Mackie Ogilvie,Sarah Curran,David A. Collier,David A. Collier +15 more
TL;DR: The data confirm that duplications and deletions at 16p13.11 represent incompletely penetrant pathogenic mutations that predispose to a range of neurodevelopmental disorders, and suggest a sex-limited effect on the penetrance of the pathological phenotypes at the 16p 13.11 locus.